BRIM Biotechnology, Inc. (TPE:6885)

BRIM Biotechnology Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	299.02	798.43	502.76	948	837.99	399.75
Short-Term Investments	682.47	360	1,346	747.63	-	23.84
Cash & Short-Term Investments	981.5	1,158	1,849	1,696	837.99	423.59
Cash Growth	-41.01%	-37.34%	9.03%	102.34%	97.83%	149.98%
Accounts Receivable	1.56	0.63	-	-	-	-
Other Receivables	13.18	41.82	23.36	6.24	0.45	0.37
Receivables	14.74	42.46	23.36	6.24	0.45	0.37
Inventory	0.76	0.67	-	-	-	-
Prepaid Expenses	49.73	6.99	4.07	11.1	10.55	6.65
Other Current Assets	0.09	0.14	0	-	-	-
Total Current Assets	1,047	1,209	1,876	1,713	848.99	430.61
Property, Plant & Equipment	10.2	14.51	11.79	6.37	7.99	3.62
Long-Term Investments	74.06	23.55	38.27	57.3	82.33	60.35
Goodwill	-	67.56	-	-	-	-
Other Intangible Assets	530.73	512.06	483.39	1.34	0.09	-
Other Long-Term Assets	1.36	1.37	1.02	0.7	0.59	0.86
Total Assets	1,663	1,828	2,411	1,779	939.99	495.44

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	0.97	0.85	-	-	-	-
Accrued Expenses	-	47.36	15.52	36.04	16.99	12.34
Current Portion of Long-Term Debt	-	2.97	-	-	-	-
Current Portion of Leases	2.43	5.84	4.23	3.48	3.63	2.85
Current Unearned Revenue	1.51	0.83	-	-	-	-
Other Current Liabilities	32.49	9.09	331.08	2.52	1.87	2.05
Total Current Liabilities	37.44	66.94	350.84	42.05	22.48	17.23
Long-Term Debt	5.47	6.46	-	-	-	-
Long-Term Leases	-	0.68	3.54	0.11	2.81	0.32
Total Liabilities	42.91	74.08	354.38	42.16	25.3	17.55

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1,331	1,332	1,315	1,158	932.54	692.54
Additional Paid-In Capital	-	1,364	1,636	1,725	589.72	454.31
Retained Earnings	-803.85	-1,021	-884.69	-1,149	-771.19	-746.92
Comprehensive Income & Other	1,016	-20.38	-9.85	2.95	163.63	77.96
Total Common Equity	1,543	1,655	2,056	1,737	914.69	477.89
Minority Interest	77.42	98.64	-	-	-	-
Shareholders' Equity	1,620	1,754	2,056	1,737	914.69	477.89
Total Liabilities & Equity	1,663	1,828	2,411	1,779	939.99	495.44

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	7.9	15.96	7.78	3.59	6.44	3.16
Net Cash (Debt)	973.6	1,142	1,841	1,692	831.55	420.42
Net Cash Growth	-41.16%	-37.94%	8.80%	103.48%	97.79%	157.57%
Net Cash Per Share	7.41	8.69	15.78	16.83	11.66	7.09
Filing Date Shares Outstanding	131.89	133.21	131.5	115.75	93.25	69.25
Total Common Shares Outstanding	131.89	133.21	131.5	115.75	93.25	69.25
Working Capital	1,009	1,142	1,525	1,671	826.51	413.38
Book Value Per Share	11.70	12.42	15.64	15.00	9.81	6.90
Tangible Book Value	1,012	1,075	1,573	1,735	914.6	477.89
Tangible Book Value Per Share	7.67	8.07	11.96	14.99	9.81	6.90
Machinery	-	15.99	9.12	6.46	4.84	3.59
Leasehold Improvements	-	3.67	3.67	3.44	3.19	3.07

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 19, 2026

Data Sources Report a data error